Publications by authors named "Christina M Zettler"
Article Synopsis
- - This study investigated the characteristics and treatment outcomes of patients with refractory or relapsed diffuse large B-cell lymphoma (R/R-DLBCL) after initial treatment with the R-CHOP regimen, noting that up to 50% of patients do not respond satisfactorily.
- - A total of 1,347 patients were included, showing that while 25.2% went on to second-line therapy, survival rates decreased significantly with each successive line of treatment, with 1-year overall survival rates at 88.5% for first-line but dropping to 62.4% for second-line.
- - The findings highlight a significant need for new and effective treatment options for R/R-DLBCL, as current therapies yield
Importance: The OlympiA trial found that 1 year of adjuvant olaparib therapy can improve distant disease-free survival and overall survival from early-stage breast cancer in patients with a germline BRCA1/2 mutation. However, olaparib, an oral poly-adenosine diphosphate ribose polymerase inhibitor, is estimated to cost approximately $14 000 per month in the US.
Objective: To estimate the incremental cost-effectiveness of adjuvant olaparib compared with no olaparib in eligible patients.
Introduction/ Background: Surgical resection remains standard of care for patients with early-stage non-small cell lung cancer (NSCLC), but research shows that adjuvant therapy can reduce the risk of disease recurrence. Our objective was to characterize disease-free survival (DFS) using real-world data.
Materials And Methods: This was a retrospective study using the COTA real-world database derived from electronic health records in the United States (US).